



JAGSONPAL PHARMACEUTICALS LIMITED Corporate Office: Nimai Tower, 3<sup>rd</sup> Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015, Haryana (India)

October 12, 2024

The Manager	The Manager
Listing Agreement	Listing Agreement
The National Stock Exchange of India Ltd.	The BSE Limited
Exchange Plaza,	Pherojbhoy Jeejeebhoy Tower
Bandra-Kurla Complex	Dalal Street,
Bandra (E), Mumbai - 400 051.	Mumbai - 400 001.
Symbol; JAGSNPHARM	SCRIP Code: 507789

Dear Madam/Sir,

## Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR")

With reference to the above we wish to inform you that one of the Promoters of the Company, Mr. Rajpal Singh Kochhar has received a settlement order No. SO/PSD/2024-25/7813 from the Securities and Exchange Board of India in respect of a settlement application filed by Mr. Rajpal Singh Kochhar for inadvertent non-compliance during the period December 2021 to March 2022 with the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015.

The settlement proceedings and consequent settlement order was not for any dealing or trading in the Securities of the Company.

The details required in terms of Regulation 30 read with schedule III of SEBI LODR is attached.

For Jagsonpal Pharmaceuticals Limited

Abhishet

Abhishek Joshi Company Secretary and Compliance Officer





## Annexure 1

Sr. No.	Particulars	Remarks
1.	Name of the Authority	Securities and Exchange Board of India (SEBI)
2.	Nature and details of the action(s) taken, initiated or order(s) passed;	Settlement Order for non-compliance with provisions of SEBI (Prohibition of Insider Trading) Regulations 2015. (SEBI PIT Regulations)
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority;	SEBI has uploaded the Settlement Order in their website <u>www.sebi.gov.in</u> on October 11, 2024.
4.	Details of the violation(s)/ contravention(s) committed or alleged to be committed;	The settlement order was passed by SEBI on an application made by Mr. Rajpal Singh Kochhar for non compliance with provisions of SEBI PIT Regulations for non closure of trading window and not maintaining Structural Digital Database during the period December 2021 to March 2022.

None

The settlement proceedings and consequent settlement order was not for any dealing or trading in the Securities of the Company .

Regulation 30 read with schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

## For Jagsonpal Pharmaceuticals Limited

Impact on financial, operation or

other activities of the listed entity, quantifiable in monetary terms to the extent possible.

Abhishek

5.

Abhishek Joshi Company Secretary and Compliance Officer